Latest Ratios: P/E Ratio -0.0x · EV/EBITDA -0.5x · ROE -457.6%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $10789 | $3763 | $21148 | — | — | — | — |
| Enterprise Value | $-5512211 | $-5519237 | $3M | — | — | — | — |
| P/E Ratio → | -0.00 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 0.00 | 0.00 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | -0.47 | -0.47 | — | — | — | — | — |
| EV / EBIT | -0.47 | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -457.6% | -457.6% | — | — | -6.0% | -1.3% | — |
| ROA | -236.4% | -236.4% | -405.0% | -67.7% | -5.2% | -1.3% | -151.4% |
| ROIC | — | — | — | — | -5.8% | -1.2% | — |
| ROCE | 612.7% | 612.7% | -1047.6% | -86.8% | -6.3% | -1.6% | -195.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.18 | 0.18 | — | — | — | — | — |
| Debt / EBITDA | 0.04 | 0.04 | — | — | — | — | — |
| Net Debt / Equity | — | -2.12 | — | — | — | -0.00 | — |
| Net Debt / EBITDA | -0.47 | -0.47 | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -915.08 | -915.08 | -317.35 | -520.11 | -45.41 | — | — |
Net cash position: cash ($6M) exceeds total debt ($468000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 2.41 | 2.41 | 0.64 | 2.27 | 5.49 | 1.17 | 1.76 |
| Quick Ratio | 2.41 | 2.41 | 0.64 | 2.27 | 5.49 | 1.17 | 1.76 |
| Cash Ratio | 2.17 | 2.17 | 0.34 | 2.09 | 5.13 | 0.11 | 1.76 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $132952 | $623846 | $111726 | $2M | $2M | $2M |
Imminent capital depletion risk
As reported in recent financial statements, Silexion Therapeutics' ROIC reached -12.8% in 2025Q2, illustrating the company's inability to generate positive returns on invested capital while it remains in the pre-revenue, clinical-stage development phase of its proprietary LODER delivery platform.
The persistent negative return on capital metrics reflect the heavy R&D burden required to advance the SiG12D-LODER program. Investors should monitor whether future clinical milestones can eventually drive a pivot toward positive capital efficiency, though current trends suggest that capital is being consumed rather than compounded.
Based on historical data, the company's accounts payable turnover has shown extreme volatility, with DPO figures reaching 38,228 days in 2026Q1, which suggests significant inconsistencies in vendor payment cycles and potential stress on the firm's liquidity management processes.
The erratic nature of these efficiency metrics is typical of a firm with limited cash reserves and irregular clinical trial expenditures. This lack of operational consistency makes it difficult to forecast the company's true cash runway without accounting for the timing of specific, non-recurring research obligations.
According to quarterly filings, the current ratio has fluctuated significantly, dropping to 1.00 in 2026Q1 from a peak of 3.97 in 2025Q3, indicating that the company's ability to cover short-term obligations is rapidly diminishing as cash reserves are depleted by ongoing clinical operations.
The compression of the current ratio suggests that the firm is approaching a point where its liquid assets may no longer provide a sufficient cushion against operational shocks. This trend warrants close attention, as it likely necessitates further dilutive financing to maintain the continuity of its clinical trials.
As disclosed in recent financial statements, the debt-to-equity ratio spiked to 1.50 in 2026Q1, a sharp increase from 0.18 in 2025Q4, which highlights the company's growing reliance on debt-like obligations despite its lack of recurring revenue or meaningful EBITDA generation.
While the absolute debt levels may appear manageable in a vacuum, the rapid deterioration of equity suggests that the company's capital structure is becoming increasingly strained. The lack of interest coverage further implies that the firm is not generating the operational cash flow necessary to service these obligations independently.
Market participants often misapply standard P/E or EV/EBITDA multiples to Silexion Therapeutics, failing to recognize that these metrics are fundamentally irrelevant for a pre-revenue biotech firm where value is derived from clinical trial success rather than current earnings.
Using traditional valuation ratios obscures the binary nature of the company's business model, where the true value lies in the potential of the LODER platform to solve solid tumor delivery challenges. Analysts should instead focus on cash runway and the probability-weighted net present value of the clinical pipeline.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SLXNW stock.
Silexion Therapeutics Ltd.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Silexion Therapeutics Ltd.'s current EV/EBITDA is -0.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
Silexion Therapeutics Ltd.'s return on equity (ROE) is -457.6%. The historical average is -155.0%.
Based on historical data, Silexion Therapeutics Ltd. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Silexion Therapeutics Ltd.'s Debt/EBITDA ratio is 0.0x, indicating low leverage. A ratio below 2x is generally considered financially healthy.